OBJECTIVE: Differences in disease outcomes between users and nonusers of hormone therapy (HT) and between users of estrogen therapy (ET) and users of estrogen + progesterone therapy (EPT) may relate to differences in serum hormone concentrations between these populations. In this study, we examined the response of serum hormone levels in healthy postmenopausal women after 1 year of HT. METHODS: A representative subsample of 200 healthy adherent participants from the active and placebo groups of the Women's Health Initiative randomized controlled clinical trials ofET (conjugated equine estrogens 0.625 mg daily) or EPT (ET plus medroxyprogesterone acetate 2.5 mg daily) were selected for the determination of selected sex hormone levels at baseline and 1 year after randomization. RESULTS: In participants receiving active ET intervention compared with placebo, estrogenic hormone levels increased from baseline to year 1 by 3.6-fold for total estrone, 2.7-fold for total estradiol, and 1.8-fold for bioavailable and free estradiol concentrations. Serum sex hormone-binding globulin concentrations also increased 2.5-fold. In contrast, progesterone levels decreased slightly in women taking exogenous EPT. The response of serum estrogens and sex hormone-binding globulin did not differ substantially with the addition of progesterone. In subgroup analyses, hormone response varied by age, ethnicity, body mass index, smoking status, vasomotor symptoms, and baseline hormone levels. CONCLUSIONS: These data provide a reference point for the serum hormone response to HT and demonstrate that the response of serum estrogens is similar for ET and EPT. The implications of the slight decrease in serum progesterone levels with EPT therapy are uncertain. Potential treatment interactions for estrogenic hormones were identified, which suggest a larger response to HT in women with low endogenous levels.
RCT Entities:
OBJECTIVE: Differences in disease outcomes between users and nonusers of hormone therapy (HT) and between users of estrogen therapy (ET) and users of estrogen + progesterone therapy (EPT) may relate to differences in serum hormone concentrations between these populations. In this study, we examined the response of serum hormone levels in healthy postmenopausal women after 1 year of HT. METHODS: A representative subsample of 200 healthy adherent participants from the active and placebo groups of the Women's Health Initiative randomized controlled clinical trials of ET (conjugated equine estrogens 0.625 mg daily) or EPT (ET plus medroxyprogesterone acetate 2.5 mg daily) were selected for the determination of selected sex hormone levels at baseline and 1 year after randomization. RESULTS: In participants receiving active ET intervention compared with placebo, estrogenic hormone levels increased from baseline to year 1 by 3.6-fold for total estrone, 2.7-fold for total estradiol, and 1.8-fold for bioavailable and free estradiol concentrations. Serum sex hormone-binding globulin concentrations also increased 2.5-fold. In contrast, progesterone levels decreased slightly in women taking exogenous EPT. The response of serum estrogens and sex hormone-binding globulin did not differ substantially with the addition of progesterone. In subgroup analyses, hormone response varied by age, ethnicity, body mass index, smoking status, vasomotor symptoms, and baseline hormone levels. CONCLUSIONS: These data provide a reference point for the serum hormone response to HT and demonstrate that the response of serum estrogens is similar for ET and EPT. The implications of the slight decrease in serum progesterone levels with EPT therapy are uncertain. Potential treatment interactions for estrogenic hormones were identified, which suggest a larger response to HT in women with low endogenous levels.
Authors: John F Randolph; MaryFran Sowers; Irina Bondarenko; Ellen B Gold; Gail A Greendale; Joyce T Bromberger; Sarah E Brockwell; Karen A Matthews Journal: J Clin Endocrinol Metab Date: 2005-09-06 Impact factor: 5.958
Authors: Veronica Wendy Setiawan; Christopher A Haiman; Frank Z Stanczyk; Loïc Le Marchand; Brian E Henderson Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-10 Impact factor: 4.254
Authors: Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: Marcia L Stefanick; Barbara B Cochrane; Judith Hsia; David H Barad; James H Liu; Susan R Johnson Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: Jennifer S Lee; Andrea Z LaCroix; LieLing Wu; Jane A Cauley; Rebecca D Jackson; Charles Kooperberg; Meryl S Leboff; John Robbins; Cora E Lewis; Douglas C Bauer; Steven R Cummings Journal: J Clin Endocrinol Metab Date: 2008-03-11 Impact factor: 5.958
Authors: T J Key; P N Appleby; G K Reeves; A Roddam; J F Dorgan; C Longcope; F Z Stanczyk; H E Stephenson; R T Falk; R Miller; A Schatzkin; D S Allen; I S Fentiman; T J Key; D Y Wang; M Dowsett; H V Thomas; S E Hankinson; P Toniolo; A Akhmedkhanov; K Koenig; R E Shore; A Zeleniuch-Jacquotte; F Berrino; P Muti; A Micheli; V Krogh; S Sieri; V Pala; E Venturelli; G Secreto; E Barrett-Connor; G A Laughlin; M Kabuto; S Akiba; R G Stevens; K Neriishi; C E Land; J A Cauley; L H Kuller; S R Cummings; K J Helzlsouer; A J Alberg; T L Bush; G W Comstock; G B Gordon; S R Miller; C Longcope Journal: J Natl Cancer Inst Date: 2003-08-20 Impact factor: 13.506
Authors: Marcelle M Dougan; Susan E Hankinson; Immaculata De Vivo; Shelley S Tworoger; Robert J Glynn; Karin B Michels Journal: Int J Cancer Date: 2015-02-05 Impact factor: 7.396
Authors: Marian L Neuhouser; Aaron K Aragaki; Ross L Prentice; JoAnn E Manson; Rowan Chlebowski; Cara L Carty; Heather M Ochs-Balcom; Cynthia A Thomson; Bette J Caan; Lesley F Tinker; Rachel Peragallo Urrutia; Jennifer Knudtson; Garnet L Anderson Journal: JAMA Oncol Date: 2015-08 Impact factor: 31.777
Authors: Jessica I Lundin; Thanh G N Ton; Andrea Z LaCroix; W T Longstreth; Gary M Franklin; Phillip D Swanson; Terri Smith-Weller; Brad A Racette; Harvey Checkoway Journal: Mov Disord Date: 2014-09-25 Impact factor: 10.338
Authors: Catherine M Jankowski; Pamela Wolfe; Sarah J Schmiege; K Sreekumaran Nair; Sundeep Khosla; Michael Jensen; Denise von Muhlen; Gail A Laughlin; Donna Kritz-Silverstein; Jaclyn Bergstrom; Richele Bettencourt; Edward P Weiss; Dennis T Villareal; Wendy M Kohrt Journal: Clin Endocrinol (Oxf) Date: 2018-12-09 Impact factor: 3.478
Authors: Shanshan Zhao; Rowan T Chlebowski; Garnet L Anderson; Lewis H Kuller; JoAnn E Manson; Margery Gass; Ruth Patterson; Thomas E Rohan; Dorothy S Lane; Shirley Aa Beresford; Sayeh Lavasani; Jacques E Rossouw; Ross L Prentice Journal: Breast Cancer Res Date: 2014-03-26 Impact factor: 6.466
Authors: Rachel H Mackey; Theresa J Fanelli; Francesmary Modugno; Jane A Cauley; Kathleen M McTigue; Maria Mori Brooks; Rowan T Chlebowski; JoAnn E Manson; Thomas L Klug; Kevin E Kip; J David Curb; Lewis H Kuller Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-08-29 Impact factor: 4.254
Authors: Carolyn J Crandall; Aaron K Aragaki; Jane A Cauley; Anne McTiernan; Joann E Manson; Garnet Anderson; Rowan T Chlebowski Journal: Breast Cancer Res Treat Date: 2011-11-01 Impact factor: 4.872
Authors: Ghada N Farhat; Neeta Parimi; Rowan T Chlebowski; Joann E Manson; Garnet Anderson; Alison J Huang; Eric Vittinghoff; Jennifer S Lee; Andrea Z Lacroix; Jane A Cauley; Rebecca Jackson; Deborah Grady; Dorothy S Lane; Lawrence Phillips; Michael S Simon; Steven R Cummings Journal: J Natl Cancer Inst Date: 2013-09-16 Impact factor: 13.506